ERBB2 and invasive ductal breast carcinoma: In an immunohistochemistry breast invasive ductal carcinoma study Oliveira-Costa and collaborators[35] demonstrated the relation between CD44 expression and HIF1-Alpha status and HER-2 expression influencing the patient prognosis[35].